Highlights
• Nanosonics gained 2.18% to $2.81 on 4 September 2026
• FY2026 annual disclosures cover revenue, cash position and commercial activity
• Company continues focus on trophon ultrasound-probe disinfection systems
• International market operations across multiple geographies reported in FY2026
Nanosonics Ltd (ASX:NAN) advanced 2.18% to $2.81 on 4 September 2026. The medical device company, known for its trophon ultrasound probe disinfection systems, continues to attract investor interest as it builds its installed base globally and works on expanding its product portfolio in the infection prevention space.
About the Company
Nanosonics is an Australian medical technology company that has developed the trophon family of ultrasound probe disinfection systems. The trophon EPR and trophon2 systems use hydrogen peroxide vapour to provide automated, standardised high-level disinfection of ultrasound probes, addressing a critical infection prevention gap in clinical settings. Nanosonics sells its devices and associated consumables across Australia, the United States, the United Kingdom, Europe and Japan, with a significant proportion of recurring Revenue coming from consumables.
Key Developments
Nanosonics' latest financial reporting covers FY2026 operations and continued development of its infection-prevention technology portfolio. The company remains focused on its trophon ultrasound-probe disinfection systems and associated products. Its FY2026 disclosures provide the latest reported financial information covering revenue, earnings, cash position, research and development, commercial activity and international market operations.
Key Catalysts to Watch
• Growth in trophon installed base in North America, Europe and Japan
• Launch or update of next-generation infection prevention products
• New geographic market entries expanding the addressable market
• Increase in consumable revenue as the installed base grows
Risks
• Reliance on a single core product category (ultrasound probe disinfection)
• Competition from chemical-based and other disinfection solutions
• Slow institutional procurement cycles in hospital settings
• Currency exposure given the majority of revenue is earned outside Australia
Conclusion
Nanosonics remains a unique ASX-listed MedTech Business with a proven product in an underserved infection prevention niche. The 2.18% gain on 4 September reflects continued investor confidence. The key near-term watch-items are the pace of installed base growth and any new product developments that could extend the company's technology Leadership beyond trophon. Investors seeking quality growth in medical technology may find NAN worth tracking closely.






Please wait processing your request...